| Karyopharm Therapeutics Inc. |
72237010106 |
XPOVIO (selinexor) 40mg (16 Tablets) |
2020-06-22 |
22000.0000 |
None |
1 |
9000 |
None |
1 |
None |
None |
None |
None |
None |
None |
| Karyopharm Therapeutics Inc. |
72237010107 |
XPOVIO (selinexor) 40mg (8 Tablets) |
2020-06-22 |
22000.0000 |
None |
1 |
9000 |
None |
1 |
None |
None |
None |
None |
None |
None |
| Karyopharm Therapeutics Inc. |
72237010103 |
XPOVIO (selinexor) 60mg (24 Tablets) |
2020-06-22 |
22000.0000 |
None |
1 |
9000 |
None |
1 |
None |
None |
None |
None |
None |
None |
| Kite Pharma, Inc. |
71287021901 |
TECARTUS™ (brexucabtagene autoleucel) 2 × 106CAR-positive viable T cells per kg of body weight, with a maximum of 2 × 108 CAR-positive viable T cells in approximately 68 mL of cell suspension for infusion |
2020-07-30 |
373000.0000 |
None |
1 |
None |
1 |
1 |
None |
None |
None |
None |
The information provided in this report is subject to general limitations and assumptions Kite has shared with OSHPD. The limitations and assumptions address gaps in guidance related to the definition and interpretation of various data elements within New Drug Reports. Additionally, consistent with the relevant statutes and regulations, the information provided in this report is limited to that which Kite believes is in the public domain or otherwise publicly available.
Kite is not aware of publicly available information related to the estimated number of patients that may be treated with TECARTUS cell therapy. Consistent with Section 127681(c) of the California Health and Safety Code, Kite is unable to provide an estimated number of patients in its report.
Kite has not provided a response to the drug acquisition related data fields for this drug product because Kite developed this drug product. |
None |